| trastuzumab deruxtecan | A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Phase 2 | Active not recruiting | 127 | Feb 10, 2027 |
| GC012F Injection | A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | 20 | Feb 1, 2027 |
| AZD9550 | A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | Phase 2 | Active not recruiting | 166 | Jan 29, 2027 |
| Savolitinib | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Phase 2 | Active not recruiting | 47 | Jan 18, 2027 |
| — | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | Phase 3 | Active not recruiting | 181 | Jan 13, 2027 |
| AZD0780 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Phase 3 | Active not recruiting | 3,103 | Jan 11, 2027 |
| Datroway | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | 768 | Jan 11, 2027 |
| — | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | Phase 3 | Active not recruiting | 314 | Jan 6, 2027 |
| AZD0780 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | Phase 3 | Active not recruiting | 473 | Jan 4, 2027 |
| Benralizumab | A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | Phase 3 | Active not recruiting | 94 | Dec 23, 2026 |
| Baxdrostat/dapagliflozin | A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | Phase 2 | Active not recruiting | 222 | Dec 10, 2026 |
| eculizumab | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | Phase 3 | Active not recruiting | 21 | Dec 7, 2026 |
| Budesonide | Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Phase 3 | Active not recruiting | 308 | Dec 2026 |
| — | A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | Active not recruiting | 339 | Nov 2, 2026 |
| Dapagliflozin 10 MG Oral Tablet | Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Phase 3 | Completed | 44 | Oct 30, 2026 |
| Durvalumab | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | Phase 2 | Completed | 61 | Oct 20, 2026 |
| — | Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | Completed | 130 | Sep 21, 2026 |
| DexamethasoneGroup III (n=25) (Dexamethasone group) | Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients | Phase 3 | Completed | 75 | Sep 20, 2026 |
| AZD0780 | A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia | Phase 2 | Completed | 76 | Sep 3, 2026 |
| Furosemide 40 mg | Salt-Sensitivity and Immunity Cell Activation | Phase 2 | Completed | 36 | Sep 1, 2026 |
| trastuzumab deruxtecan | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Phase 3 | Active not recruiting | 490 | Aug 31, 2026 |
| AZD2936 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 2 | Active not recruiting | 212 | Aug 28, 2026 |
| AZD9833 | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | Phase 3 | Active not recruiting | 1,370 | Aug 24, 2026 |
| AZD7798 | Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy | Phase 2 | Active not recruiting | 24 | Aug 20, 2026 |
| Nexium 20mg | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | Phase 3 | Completed | 53 | Aug 10, 2026 |
| Danicopan | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | Phase 3 | Active not recruiting | 80 | Jul 31, 2026 |
| Bevespi | Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD | Phase 2 | Completed | 25 | Jul 31, 2026 |
| Olaparib | D9319C00001- 1L OC Mono Global RCT | Phase 3 | Active not recruiting | 366 | Jul 27, 2026 |
| Ravulizumab | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | 12 | Jul 15, 2026 |
| Tezepelumab | Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Phase 3 | Active not recruiting | 368 | Jul 14, 2026 |
| Dapagliflozin | Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema | Phase 2 | Completed | 56 | Jul 14, 2026 |
| Tagrisso | To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Phase 2 | Active not recruiting | 76 | Jul 7, 2026 |
| trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Phase 3 | Active not recruiting | 1,157 | Jul 6, 2026 |
| Durvalumab | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | Phase 2 | Active not recruiting | 58 | Jul 1, 2026 |
| Oleclumab | A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) | Phase 2 | Active not recruiting | 30 | Jun 30, 2026 |
| Magnesium | A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures | Phase 2 | Completed | 120 | Jun 30, 2026 |
| Durvalumab | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | 1,051 | Jun 30, 2026 |
| ALXN2420 | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly | Phase 2 | Terminated | 8 | Jun 24, 2026 |
| Cabazitaxel | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | Phase 2 | Completed | 96 | Jun 10, 2026 |